Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

2.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
3.

Bone microarchitecture and bone mineral density in multiple sclerosis.

Olsson A, Oturai AB, Søndergaard HB, Sellebjerg F, Oturai PS.

Acta Neurol Scand. 2018 Mar;137(3):363-369. doi: 10.1111/ane.12884. Epub 2017 Dec 21.

PMID:
29270986
4.

The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement.

Hedström AK, Katsoulis M, Hössjer O, Bomfim IL, Oturai A, Sondergaard HB, Sellebjerg F, Ullum H, Thørner LW, Gustavsen MW, Harbo HF, Obradovic D, Gianfrancesco MA, Barcellos LF, Schaefer CA, Hillert J, Kockum I, Olsson T, Alfredsson L.

Eur J Epidemiol. 2017 Oct;32(10):909-919. doi: 10.1007/s10654-017-0250-2. Epub 2017 Jun 8.

5.

Relationship between soluble CD25 and gene expression in healthy individuals and patients with multiple sclerosis.

Buhelt S, Ratzer RL, Christensen JR, Börnsen L, Sellebjerg F, Søndergaard HB.

Cytokine. 2017 May;93:15-25. doi: 10.1016/j.cyto.2017.04.024. Epub 2017 May 13.

PMID:
28511943
6.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
7.

Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis.

Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzer R, Romme Nielsen B, Søndergaard HB, von Essen MR, Sellebjerg F.

J Leukoc Biol. 2017 May;101(5):1211-1220. doi: 10.1189/jlb.3A0616-267R. Epub 2017 Feb 8.

PMID:
28179539
8.

Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis.

Petersen ER, Søndergaard HB, Oturai AB, Jensen P, Sorensen PS, Sellebjerg F, Börnsen L.

Mult Scler Relat Disord. 2016 Nov;10:66-72. doi: 10.1016/j.msard.2016.09.001. Epub 2016 Sep 6.

PMID:
27919501
9.

Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Nov;10:169-173. doi: 10.1016/j.msard.2016.10.005. Epub 2016 Oct 26.

PMID:
27919484
10.

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Sep;9:104-9. doi: 10.1016/j.msard.2016.06.010. Epub 2016 Jun 27.

PMID:
27645354
11.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

12.

Association between age at onset of multiple sclerosis and vitamin D level-related factors.

Laursen JH, Søndergaard HB, Sørensen PS, Sellebjerg F, Oturai AB.

Neurology. 2016 Jan 5;86(1):88-93. doi: 10.1212/WNL.0000000000002075. Epub 2015 Oct 7.

PMID:
26446064
13.

Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.

Oturai DB, Søndergaard HB, Börnsen L, Sellebjerg F, Christensen JR.

Scand J Immunol. 2016 Jan;83(1):72-80. doi: 10.1111/sji.12391.

14.

Class II HLA interactions modulate genetic risk for multiple sclerosis.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J; International IBD Genetics Consortium (IIBDGC), Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Søndergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G.

Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.

15.

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.

Börnsen L, Romme Christensen J, Ratzer R, Hedegaard C, Søndergaard HB, Krakauer M, Hesse D, Nielsen CH, Sorensen PS, Sellebjerg F.

PLoS One. 2015 Mar 4;10(3):e0118830. doi: 10.1371/journal.pone.0118830. eCollection 2015.

16.

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect.

Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, Kapel C, Roepstorff A, Thamsborg SM, Melbye M, Siebner H, Søndergaard HB, Sellebjerg F, Sørensen PS.

Mult Scler. 2015 Nov;21(13):1723-9. doi: 10.1177/1352458514568173. Epub 2015 Feb 19.

PMID:
25698173
17.

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

Goris A, Pauwels I, Gustavsen MW, van Son B, Hilven K, Bos SD, Celius EG, Berg-Hansen P, Aarseth J, Myhr KM, D'Alfonso S, Barizzone N, Leone MA, Martinelli Boneschi F, Sorosina M, Liberatore G, Kockum I, Olsson T, Hillert J, Alfredsson L, Bedri SK, Hemmer B, Buck D, Berthele A, Knier B, Biberacher V, van Pesch V, Sindic C, Bang Oturai A, Søndergaard HB, Sellebjerg F, Jensen PE, Comabella M, Montalban X, Pérez-Boza J, Malhotra S, Lechner-Scott J, Broadley S, Slee M, Taylor B, Kermode AG, Gourraud PA; International Multiple Sclerosis Genetics Consortium, Sawcer SJ, Andreassen BK, Dubois B, Harbo HF.

Brain. 2015 Mar;138(Pt 3):632-43. doi: 10.1093/brain/awu405. Epub 2015 Jan 22.

18.

Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis.

Laursen JH, Søndergaard HB, Albrechtsen A, Frikke-Schmidt R, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A.

Mult Scler. 2015 Oct;21(11):1414-22. doi: 10.1177/1352458514563590. Epub 2014 Dec 22.

PMID:
25533295
19.

Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general.

Gustavsen MW, Viken MK, Celius EG, Berge T, Mero IL, Berg-Hansen P, Aarseth JH, Myhr KM, Søndergaard HB, Sellebjerg F, Oturai AB, Hillert J, Alfredsson L, Olsson T, Kockum I, Lie BA, Harbo HF.

J Neuroimmunol. 2014 Sep 15;274(1-2):174-9. doi: 10.1016/j.jneuroim.2014.06.024. Epub 2014 Jul 6.

PMID:
25037176
20.

Prediction of response to interferon therapy in multiple sclerosis.

Sellebjerg F, Søndergaard HB, Koch-Henriksen N, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2014 Oct;130(4):268-75. doi: 10.1111/ane.12269. Epub 2014 Jun 18.

PMID:
24943672
21.

JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants.

Sundqvist E, Buck D, Warnke C, Albrecht E, Gieger C, Khademi M, Lima Bomfim I, Fogdell-Hahn A, Link J, Alfredsson L, Søndergaard HB, Hillert J; International Multiple Sclerosis Genetics Consortium, Oturai AB, Hemmer B, Kockum I, Olsson T.

PLoS Pathog. 2014 Apr 24;10(4):e1004084. doi: 10.1371/journal.ppat.1004084. eCollection 2014 Apr. Erratum in: PLoS Pathog. 2014 Sep;10(9):e1004430. Hemme, Bernhard [corrected to Hemmer, Bernhard].

22.

Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.

Ratzer R, Søndergaard HB, Christensen JR, Börnsen L, Borup R, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1841-8. doi: 10.1177/1352458513500553. Epub 2013 Oct 1.

PMID:
24085340
23.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

24.

Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients.

Leone MA, Barizzone N, Esposito F, Lucenti A, Harbo HF, Goris A, Kockum I, Oturai AB, Celius EG, Mero IL, Dubois B, Olsson T, Søndergaard HB, Cusi D, Lupoli S, Andreassen BK; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Myhr KM, Guerini FR; PROGEMUS Group; PROGRESSO Group, Comi G, Martinelli-Boneschi F, D'Alfonso S.

PLoS One. 2013 Jun 13;8(6):e64408. doi: 10.1371/journal.pone.0064408. Print 2013.

25.

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1849-57. doi: 10.1177/1352458513490542. Epub 2013 Jun 17.

PMID:
23773985
26.

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.

Møller M, Søndergaard HB, Koch-Henriksen N, Sorensen PS, Sellebjerg F, Oturai AB.

Acta Neurol Scand. 2014 Jan;129(1):27-31. doi: 10.1111/ane.12145. Epub 2013 May 14.

PMID:
23668375
27.

Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Mero IL, Gustavsen MW, Sæther HS, Flåm ST, Berg-Hansen P, Søndergaard HB, Jensen PE, Berge T, Bjølgerud A, Muggerud A, Aarseth JH; International Multiple Sclerosis Genetics Consortium, Myhr KM, Celius EG, Sellebjerg F, Hillert J, Alfredsson L, Olsson T, Oturai AB, Kockum I, Lie BA, Andreassen BK, Harbo HF.

PLoS One. 2013;8(3):e58352. doi: 10.1371/journal.pone.0058352. Epub 2013 Mar 5.

28.

Identification and Characterization of a Novel Nontranslated Sequence Variant of the Human Intestinal Di-/Tripeptide Transporter, hPEPT1.

Søndergaard HB, Nielsen CU, Brodin B.

Int J Pept. 2012;2012:743472. doi: 10.1155/2012/743472. Epub 2012 Dec 30.

29.

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Börnsen L, Christensen JR, Ratzer R, Oturai AB, Sørensen PS, Søndergaard HB, Sellebjerg F.

PLoS One. 2012;7(11):e47578. doi: 10.1371/journal.pone.0047578. Epub 2012 Nov 30.

30.

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis.

Romme Christensen J, Börnsen L, Hesse D, Krakauer M, Sørensen PS, Søndergaard HB, Sellebjerg F.

J Neuroinflammation. 2012 Sep 14;9:215. doi: 10.1186/1742-2094-9-215.

31.

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Sellebjerg F, Krakauer M, Limborg S, Hesse D, Lund H, Langkilde A, Søndergaard HB, Sørensen PS.

PLoS One. 2012;7(6):e35927. doi: 10.1371/journal.pone.0035927. Epub 2012 Jun 6.

32.

Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.

Sellebjerg F, Hesse D, Limborg S, Lund H, Søndergaard HB, Krakauer M, Sørensen PS.

Mult Scler. 2013 Feb;19(2):179-87. doi: 10.1177/1352458512450353. Epub 2012 May 31.

PMID:
22653658
33.

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS.

Eur J Neurol. 2012 Oct;19(10):1311-7. doi: 10.1111/j.1468-1331.2012.03721.x. Epub 2012 May 5.

PMID:
22564111
34.

Genetic association of multiple sclerosis with the marker rs391745 near the endogenous retroviral locus HERV-Fc1: analysis of disease subtypes.

Hansen B, Oturai AB, Harbo HF, Celius EG, Nissen KK, Laska MJ, Søndergaard HB, Petersen T, Nexø BA.

PLoS One. 2011;6(10):e26438. doi: 10.1371/journal.pone.0026438. Epub 2011 Oct 25.

35.

Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.

Sellebjerg F, Hedegaard CJ, Krakauer M, Hesse D, Lund H, Nielsen CH, Søndergaard HB, Sørensen PS.

Mult Scler. 2012 Mar;18(3):305-13. doi: 10.1177/1352458511420268. Epub 2011 Oct 21.

PMID:
22020419
36.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

37.

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators.

Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.

PMID:
21742556
38.

Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655.

Søndergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Lindén M, Mero IL, Myhr KM, Celius EG, Harbo HF, Christensen JR, Börnsen L, Sørensen PS, Oturai AB.

Eur J Hum Genet. 2011 Oct;19(10):1100-3. doi: 10.1038/ejhg.2011.88. Epub 2011 May 25.

39.

The etiology of multiple sclerosis: genetic evidence for the involvement of the human endogenous retrovirus HERV-Fc1.

Nexø BA, Christensen T, Frederiksen J, Møller-Larsen A, Oturai AB, Villesen P, Hansen B, Nissen KK, Laska MJ, Petersen TS, Bonnesen S, Hedemand A, Wu T, Wang X, Zhang X, Brudek T, Maric R, Søndergaard HB, Sellebjerg F, Brusgaard K, Kjeldbjerg AL, Rasmussen HB, Nielsen AL, Nyegaard M, Petersen T, Børglum AD, Pedersen FS.

PLoS One. 2011 Feb 2;6(2):e16652. doi: 10.1371/journal.pone.0016652.

40.

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Sørensen PS, Sellebjerg F.

Eur J Neurol. 2011 Feb;18(2):266-72. doi: 10.1111/j.1468-1331.2010.03116.x.

PMID:
20561040
41.

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.

Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F.

Neurology. 2010 May 4;74(18):1455-62. doi: 10.1212/WNL.0b013e3181dc1a94.

PMID:
20439848
42.

Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L.

Am J Hum Genet. 2010 Feb 12;86(2):285-91. doi: 10.1016/j.ajhg.2010.01.017.

43.

A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis.

Mero IL, Lorentzen AR, Ban M, Smestad C, Celius EG, Aarseth JH, Myhr KM, Link J, Hillert J, Olsson T, Kockum I, Masterman T, Oturai AB, Søndergaard HB, Sellebjerg F, Saarela J, Kemppinen A, Elovaara I, Spurkland A, Dudbridge F, Lie BA, Harbo HF.

Eur J Hum Genet. 2010 Apr;18(4):502-4. doi: 10.1038/ejhg.2009.195. Epub 2009 Nov 4.

44.

Cloning of the pig PEPT2 (pPEPT2) and characterization of the effects of epidermal growth factor (EGF) on pPEPT2-mediated peptide uptake in the renal porcine cell line LLC-PK1.

Søndergaard HB, Bravo SA, Nielsen CU, Frokjaer S, Brodin B.

Eur J Pharm Sci. 2008 Apr 23;33(4-5):332-42. doi: 10.1016/j.ejps.2008.01.001. Epub 2008 Jan 6.

PMID:
18295462
45.

hPEPT1 is responsible for uptake and transport of Gly-Sar in the human bronchial airway epithelial cell-line Calu-3.

Søndergaard HB, Brodin B, Nielsen CU.

Pflugers Arch. 2008 Jun;456(3):611-22. Epub 2007 Dec 20.

PMID:
18094991

Supplemental Content

Loading ...
Support Center